BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
월요일, 9월 14

Ascendis Pharma AS

ASNDNASDAQ
Trade with Public
Trade with Public
$264.92
1.410.53%
가까이에: Sep 14, 5:00 PM EST
$266.05
1.130.43%
시간외: 6:41 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Ascendis Pharma Financials

Ascendis Pharma (ASND) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.78 by 34.62 percent. This is a 212.9 percent increase over losses of $(0.93) per share from
Benzinga Newsdesk

PRO
Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 119.28 percent increase over losses of $(1.66) per share from
Benzinga Newsdesk

Ascendis Pharma Earnings Report: Q4 Overview

Benzinga Insights

PRO
Ascendis Pharma Q4 EPS $(0.64) Misses $(0.06) Estimate, Sales $288.127M Miss $289.720M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.06) by 966.67 percent. This is a 5.88 percent increase over losses of $(0.68) per share from
Benzinga Newsdesk

Earnings Scheduled For February 11, 2026

Benzinga Insights

A Glimpse of Ascendis Pharma's Earnings Potential

Benzinga Insights

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved